Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18437732 | TREATMENT OF MAJOR DEPRESSIVE DISORDER | February 2024 | June 2025 | Abandon | 16 | 0 | 1 | No | No |
| 18500081 | 6-(6-BROMO-2-OXO-2H-CHROMEN-3-YL)-4-(2,4-DICHLOROPHENYL)-2-ALKOXYNICOTINONITRILE AS AN ANTIMICROBIAL COMPOUND | November 2023 | October 2024 | Allow | 12 | 2 | 1 | Yes | No |
| 18383407 | ETHYL-1-(SUBSTITUTEDBENZOYL)-5-METHYLPYRROLO[1,2-A]QUINOLINE-3-CARBOXYLATES AS ANTICANCER AGENTS | October 2023 | August 2024 | Allow | 10 | 2 | 0 | No | No |
| 18372599 | 1-CYCLOPROPYL-7-(4-((5-(2,4-DICHLOROBENZYLIDENEAMINO)-2-THIOXO-1,3,4-THIADIAZOL-3(2H)-YL)METHYL)PIPERAZIN-1-YL)-6-FLUORO-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID AS AN ANTI-INFLAMMATORY COMPOUND | September 2023 | January 2024 | Allow | 3 | 0 | 1 | No | No |
| 18139405 | ANTIVIRAL COMPOUNDS | April 2023 | August 2024 | Allow | 15 | 1 | 1 | Yes | No |
| 18300890 | COMPOSITION AND TREATMENT FOR CANCER WITH MUTATIONS | April 2023 | July 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18117193 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | March 2023 | March 2025 | Allow | 25 | 1 | 1 | Yes | No |
| 18103843 | ABIETANE TYPE DITERPENE COMPOUND, PREPARATION METHOD AND APPLICATION THEREOF | January 2023 | February 2024 | Allow | 12 | 0 | 1 | Yes | No |
| 18069028 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | December 2022 | April 2024 | Allow | 16 | 1 | 1 | Yes | No |
| 18083793 | LIDOCAINE-CONTAINING PATCH | December 2022 | August 2024 | Allow | 20 | 2 | 0 | Yes | No |
| 18061150 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | December 2022 | August 2024 | Allow | 20 | 1 | 1 | Yes | No |
| 18050907 | TREATMENT OF MAJOR DEPRESSIVE DISORDER | October 2022 | March 2024 | Abandon | 17 | 1 | 0 | No | No |
| 17973581 | PREPARATION METHOD AND APPLICATION OF SUPRAMOLECULAR NANO-DRUG BASED ON IRINOTECAN AND NIRAPARIB | October 2022 | November 2024 | Abandon | 24 | 2 | 1 | No | No |
| 18047707 | Topical Formulation of Disease-Modifying Antirheumatic Drug (DMARDs) for the Treatment of Rheumatoid Arthritis, Melanoma, Squamous Cell Carcinoma, Atopic Dermatitis, and Psoriasis | October 2022 | October 2024 | Allow | 24 | 2 | 1 | Yes | No |
| 17964110 | PYRAZOLE DERIVATIVES WITH ANTICANCER ACTIVITY | October 2022 | January 2024 | Allow | 15 | 1 | 0 | No | No |
| 17898920 | USE OF VALERIC ACID IN PREPARATION OF DRUG FOR PREVENTING AND TREATING DIABETES | August 2022 | September 2024 | Abandon | 24 | 2 | 0 | No | No |
| 17547704 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | December 2021 | May 2025 | Allow | 41 | 4 | 2 | Yes | No |
| 17610195 | SOLID STATE FORMS OF TAFAMIDIS AND SALTS THEREOF | November 2021 | April 2025 | Allow | 41 | 0 | 1 | Yes | No |
| 17607311 | OXAAZAQUINAZOLINE-7(8H)-KETONE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | October 2021 | April 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17438560 | METHODS OF TREATING ORGANIC ACIDEMIAS | September 2021 | May 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17438857 | SMALL MOLECULES THAT BIND CYCLIN-DEPENDENT KINASE INHIBITOR 1B (P27KIP1) | September 2021 | January 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17438067 | BENZIDINE COMPOUND AND APPLICATION THEREOF | September 2021 | March 2025 | Allow | 42 | 1 | 1 | Yes | No |
| 17436301 | Dihydro-Spiro[Indoline-3:1'-Isoquinolin]-2-Ones and Their Analogues and Derivatives and Methods of Treating Cancer and Other Diseases | September 2021 | February 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17432927 | TREATMENT OF PSORIASIS WITH TOPICAL TAPINAROF-TAZAROTENE COMBINATION COMPOSITIONS | August 2021 | April 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17431626 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE (5-MEO-DMT) FOR TREATING DEPRESSION | August 2021 | June 2024 | Abandon | 34 | 0 | 0 | No | No |
| 17404529 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | August 2021 | April 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17430371 | USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) | August 2021 | December 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17430447 | L-PIPECOLIC ACID COCRYSTAL OF CANNABIDIOL | August 2021 | March 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17428856 | IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | August 2021 | December 2024 | Allow | 40 | 0 | 1 | Yes | No |
| 17427015 | COMBINATION OF A CDK INHIBITOR AND A PIM INHIBITOR | July 2021 | December 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17425956 | TREATMENT OF SKIN DISORDERS WITH TOPICAL TAPINAROF COMBINATION COMPOSITIONS | July 2021 | February 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17425608 | USE OF GERANYLFLAVONE A IN PREPARATION OF DRUG FOR PROMOTING HEALING OF WOUNDS | July 2021 | November 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17424810 | THEOPHYLLINE DERIVATIVES WITH NEMATOCIDAL ACTIVITY, THEIR AGRONOMIC COMPOSITIONS AND RELATIVE USE | July 2021 | March 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17424240 | Heterocyclic derivatives | July 2021 | December 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17379855 | COMPOSITIONS AND METHODS OF TREATMENT | July 2021 | January 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17422598 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS | July 2021 | March 2025 | Allow | 44 | 1 | 1 | No | No |
| 17421348 | IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS | July 2021 | March 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17296730 | COMPOUNDS TARGETING MUTANT CALRETICULIN | May 2021 | May 2025 | Allow | 47 | 2 | 1 | Yes | No |
| 17296143 | PYRIMIDINE AND FIVE-MEMBERED NITROGEN HETEROCYCLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF | May 2021 | October 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17289709 | 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | April 2021 | November 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17242961 | PHARMACEUTICAL COMPOSITION CONTAINING AN ANTITUMOR AGENT | April 2021 | July 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17287680 | SERINE DERIVATIVE COMPOUND FOR THE PREVENTION OR TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES | April 2021 | March 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17287736 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | April 2021 | January 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17287417 | PHARMACEUTICAL APPLICATION FOR THE INHIBITION OF NOVEL CORONAVIRUSES BY MYRICETIN | April 2021 | January 2025 | Abandon | 45 | 3 | 0 | No | No |
| 17284161 | AZD3355 (LESOGABERAN) FOR TREATMENT AND PREVENTION OF NONALCOHOLIC STEATOHEPATITIS (NASH), LIVER FIBROSIS, AND OTHER LIVER CONDITIONS | April 2021 | October 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17225200 | ANTITUMOR AGENT FOR ACUTE MYELOID LEUKEMIA | April 2021 | June 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17282064 | 2,6-DIMETHYL-N-((PYRIDlN-4-YL)METHYL)IMIDAZO[1,2-B]PYRIDAZIN-8-AMINE AND 2,5-DIMETHYL-N-[(PYRIDlN-4-YL)METHYL]PYRAZOLO[1,5-A]PYRIMIDlN-7-AMINE DERIVATIVES FOR TREATING VIRAL INFECTIONS | April 2021 | January 2025 | Allow | 46 | 2 | 1 | Yes | No |
| 17282108 | BENZIMIDAZOLE DERIVATIVE FOR USE IN THE TREATMENT OF INFLAMMATORY DISORDERS | April 2021 | September 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17278579 | Phosphate Derivatives of Indole Compounds and Their Use | March 2021 | June 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17276178 | CYCLOHEPTYL ACIDS AS LPA ANTAGONISTS | March 2021 | February 2025 | Abandon | 47 | 2 | 1 | No | No |
| 17275720 | TREATMENT OF CHOLANGIOCARCINOMA | March 2021 | June 2024 | Allow | 39 | 1 | 0 | No | No |
| 17275902 | PESTICIDALLY ACTIVE AZOLE-AMIDE COMPOUNDS | March 2021 | September 2024 | Abandon | 42 | 1 | 1 | No | No |
| 17187931 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | March 2021 | April 2025 | Abandon | 50 | 2 | 1 | No | No |
| 17053037 | DRUG FOR USE IN COMBINATION, AND USE THEREOF FOR PREPARING DRUGS FOR TREATMENT OF HIGH-GRADE BRAIN TUMORS IN RESPONSE TO INEFFECTIVE STANDARD TREATMENT FOR POSTOPERATIVE RECURRENCE | February 2021 | December 2024 | Abandon | 49 | 2 | 0 | No | No |
| 17262249 | 4,5-DIHYDROXY-2-(4-METHYLBENZYL)ISOPHTHALONITRILE SOLVATES AND CRYSTALLINE FORMS THEREOF | January 2021 | May 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17259903 | COMPOSITION FOR PROMOTING BIOSYNTHESIS OF ELASTIN AND COLLAGEN IN CONNECTIVE TISSUE | January 2021 | May 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17147176 | ANDROGEN COMPOSITION FOR TREATING AN OPTHALMIC CONDITION | January 2021 | July 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17259757 | COMPOSITION OF FUSED TRICYCLIC GAMMA-AMINO ACID DERIVATIVES AND THE PREPARATION THEREOF | January 2021 | October 2024 | Allow | 45 | 2 | 1 | Yes | No |
| 17109531 | Treatment of Female Genital Schistosomiasis | December 2020 | September 2024 | Abandon | 45 | 2 | 0 | No | No |
| 16971736 | BEXAROTENE DERIVATIVES AND THEIR USE IN TREATING CANCER | August 2020 | March 2025 | Allow | 55 | 3 | 1 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner LEE, CHIHYI NMN works in Art Unit 1628 and has examined 59 patent applications in our dataset. With an allowance rate of 35.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.
Examiner LEE, CHIHYI NMN's allowance rate of 35.6% places them in the 3% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by LEE, CHIHYI NMN receive 0.98 office actions before reaching final disposition. This places the examiner in the 12% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by LEE, CHIHYI NMN is 41 months. This places the examiner in the 5% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +88.4% benefit to allowance rate for applications examined by LEE, CHIHYI NMN. This interview benefit is in the 100% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 33.3% of applications are subsequently allowed. This success rate is in the 65% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 58.3% of cases where such amendments are filed. This entry rate is in the 81% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 57.1% are granted (fully or in part). This grant rate is in the 72% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 9.5% of allowed cases (in the 87% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.